1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma : a 10-year follow-up
Pulczynski, Elisa Jacobsen ; Simonsen, Mikkel Runason ; Kuittinen, Outi ; Fagerli, Unn Merete ; Erlanson, Martin ; Fluge, Øystein ; Leppä, Sirpa ; Østenstad, Bjørn ; Fosså, Alexander and Eriksson, Mikael LU
, et al.
(2024)
In Haematologica
109(7).
p.2359-2363
- Contribution to journal › Letter
- 2022
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
- Contribution to journal › Article
- 2020
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
- Contribution to journal › Article
- 2015
-
Mark
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase 2 study by The Nordic Lymphoma Group.
Pulczynski, Elisa J ; Kuittinen, Outi ; Erlanson, Martin ; Hagberg, Hans ; Fosså, Alexander ; Eriksson, Mikael LU
; Nordstrøm, Marie
; Ostenstad, Bjørn
; Fluge, Oystein
and Leppä, Sirpa
, et al.
(2015)
In Haematologica
100(4).
p.534-540
- Contribution to journal › Article
- 2014
-
Mark
Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
- Contribution to journal › Article
- 2012
-
Mark
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Riihijarvi, Sari ; Nurmi, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Fjordén, Karin LU ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2012)
In European Journal of Haematology
89(5).
p.395-402
- Contribution to journal › Article
- 2010
-
Mark
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
Riihuarvi, Sari ; Nyman, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2010)
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
In Blood
116(21).
p.1686-1686
- Contribution to journal › Published meeting abstract
-
Mark
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
(2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1281-1281
- Contribution to journal › Published meeting abstract
-
Mark
R CHOEP 14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3 Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years
(2010) 52nd Annual Meeting of the American-Society-of-Hematology (ASH) In Blood 116(21). p.1157-1157
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18-64 Years.
- Contribution to journal › Published meeting abstract